PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsMercaptopurine
Purinethol, Xaluprine (previously mercaptopurine nova laboratories)(mercaptopurine)
Purinethol, Purixan, Xaluprine (mercaptopurine) is a small molecule pharmaceutical. Mercaptopurine was first approved as Purinethol on 1982-01-01. It is used to treat b-cell chronic lymphocytic leukemia, non-hodgkin lymphoma, and precursor cell lymphoblastic leukemia-lymphoma in the USA. It has been approved in Europe to treat lymphoid leukemia.
Download report
Favorite
Drugs Approved for Childhood Cancers
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Purinethol, Purixan (generic drugs available since 2004-02-11)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mercaptopurine
Tradename
Company
Number
Date
Products
PURIXANNova LaboratoriesN-205919 RX2014-04-28
1 products, RLD, RS
PURINETHOLStason PharmaceuticalsN-009053 RX1982-01-01
1 products, RLD
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
b-cell chronic lymphocytic leukemia—D015451C91.1
non-hodgkin lymphoma—D008228C85.9
precursor cell lymphoblastic leukemia-lymphoma—D054198C91.0
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01B: Antimetabolites
— L01BB: Purine analogs, antimetabolites antineoplastic
— L01BB02: Mercaptopurine
HCPCS
Code
Description
S0108
Mercaptopurine, oral, 50 mg
Clinical
Clinical Trials
259 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.01852391711122
Crohn diseaseD003424EFO_0000384K503425516
Inflammatory bowel diseasesD015212EFO_0003767————41115
Ulcerative colitisD003093EFO_0000729K51—114612
Promyelocytic leukemia acuteD015473—C92.4——43—7
PancreatitisD010195HP_0001733K85———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C9522530—456
LymphomaD008223—C85.9—210——12
Myeloid leukemia acuteD015470—C92.0115—29
Philadelphia chromosomeD010677——242——6
Down syndromeD004314EFO_0001064Q90—23——5
T-cell leukemiaD015458———32——3
Langerhans-cell histiocytosisD006646—C96.6—13——3
B-cell leukemiaD015448———21——2
MucositisD052016EFO_1001898———1——1
CardiotoxicityD066126EFO_1001482———1——1
Show 2 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Biphenotypic leukemia acuteD015456—C95.022———3
Non-hodgkin lymphomaD008228—C85.912———2
Systemic lupus erythematosusD008180HP_0002725M32—1——12
GlioblastomaD005909EFO_0000515—12———2
Burkitt lymphomaD002051—C83.711———1
NeutropeniaD009503—D70—1———1
ThrombocytopeniaD013921HP_0001873D69.6—1———1
Hermanski-pudlak syndromeD022861—E70.331—1———1
ColitisD003092EFO_0003872K52.9—1———1
LymphocytosisD008218———1———1
Show 9 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug-related side effects and adverse reactionsD064420—T88.7————33
Thrombocytopenic purpura idiopathicD016553EFO_0007160D69.3————11
PsoriasisD011565EFO_0000676L40————11
Squamous intraepithelial lesionsD000081483——————11
Ataxia telangiectasiaD001260Orphanet_100G11.3————11
Herpes zosterD006562EFO_0006510B02————11
Clostridioides difficileD016360NCBITaxon_1496—————11
Cytomegalovirus infectionsD003586EFO_0001062B25————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMercaptopurine
INNmercaptopurine
Description
Purine-6-thiol is a thiol that is the tautomer of mercaptopurine. It has a role as an antineoplastic agent and an antimetabolite. It is a tautomer of a mercaptopurine. It derives from a hydride of a 7H-purine.
Classification
Small molecule
Drug classaptamers, classical and mirror
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O.S=c1[nH]cnc2nc[nH]c12
Identifiers
PDB—
CAS-ID6112-76-1
RxCUI—
ChEMBL IDCHEMBL1200751
ChEBI ID31822
PubChem CID667490
DrugBankDB01033
UNII IDPKK6MUZ20G (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Mercaptopurine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 13,755 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
10,401 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use